Table 2.

Inhibitors associated with blocking p53 aggregation

Inhibitor	Type	Targeting the p53 mutation site	Principle	Experiment
ReACp53[109]	A designed 17-residue peptide Inhibitor	Target R175 and R248 in HGSOC, have no effect on cells with folded wild-type p53	p53 amyloid spine structure is used to design ReACp53 ((R9)RPILTRITLE). Targeting p53 segment 251–257	In vitro and in vivo
LI [110]	Bifunctional ligands	Y220C	Zn-free p53 exhibits accelerated protein aggregation, and LI modulate mutant p53 aggregation and restore zinc binding using a metallochaperone approach	In vitro and in vivo
Tripyridylamide ADH-6[111]	Protein mimetic amyloid inhibitor	Target R175 and R248 in Pancreatic cancer, have no effect on cells with folded wild-type p53	α-Helix mimetics are small molecules that imitate the topography of the most commonly occurring protein secondary structure, serving as effective antagonists of protein–protein interactions (PPIs) at the interaction interface	In vitro and in vivo